Vision

At Skyline Diagnostics we firmly believe that we can revolutionize the practice of treating cancer, starting with blood cancers. Through an innovative combination of life sciences and sophisticated information technology we turn personalized cancer treatment into reality by translating scientific knowledge into state-of-the-art clinical diagnostics.

History

The discovery of clinically applicable gene signatures from cancer cells in AML patients led to the founding of Skyline Diagnostics in 2005. The investigators and clinicians of the Departments of Hematology and Bioinformatics of the Erasmus Medical Center, among whom Chief Scientific Officer professor Bob Löwenberg, teamed up with biotech...

Company Profile

Skyline Diagnostics develops and markets microarray-based diagnostic tests using molecular signatures for personalized medicine in oncology. With its infrastructure, expertise and access to large collections of well-defined clinical samples, Skyline is an excellent partner for discovery, development and commercialization of new diagnostic assays and devices.

The team

Awards and Recognition

FEM Tech Top 25 Innovative Companies AwardSkyline was awarded one of the 25 most promising start-up technology companies of the Netherlands by the FEM Business Magazine.                 From: FEM Business, June 8 2008Medtech Top 25 AwardOn November 20, 2008 Skyline presented at the Medtech Summit, which highlighted Skyline as one of...

Careers

Skyline Diagnostics B.V. is a young ambitious biotech company started by the departments Hematology and Bioinformatics of the Erasmus Medical Center in Rotterdam.We develop in vitro diagnostic microarrays for oncology based on the Affymetrix™ Genechip® technology.

Press Releases

2011, September 6: Skyline Diagnostics and Clavis Pharma to collaborate on patient selection biomarker discovery for leukemia drug elacytarabine